GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luye Pharma Group Ltd (STU:LUP) » Definitions » EV-to-EBITDA

Luye Pharma Group (STU:LUP) EV-to-EBITDA : 5.99 (As of Sep. 23, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Luye Pharma Group EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Luye Pharma Group's enterprise value is €1,599.9 Mil. Luye Pharma Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €267.2 Mil. Therefore, Luye Pharma Group's EV-to-EBITDA for today is 5.99.

The historical rank and industry rank for Luye Pharma Group's EV-to-EBITDA or its related term are showing as below:

STU:LUP' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.7   Med: 10.21   Max: 26.84
Current: 6.12

During the past 13 years, the highest EV-to-EBITDA of Luye Pharma Group was 26.84. The lowest was 5.70. And the median was 10.21.

STU:LUP's EV-to-EBITDA is ranked better than
82.72% of 712 companies
in the Drug Manufacturers industry
Industry Median: 13.99 vs STU:LUP: 6.12

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-09-23), Luye Pharma Group's stock price is €0.324. Luye Pharma Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.018. Therefore, Luye Pharma Group's PE Ratio for today is 18.00.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Luye Pharma Group EV-to-EBITDA Historical Data

The historical data trend for Luye Pharma Group's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luye Pharma Group EV-to-EBITDA Chart

Luye Pharma Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.36 7.61 16.07 8.66 7.77

Luye Pharma Group Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.07 - 8.66 - 7.77

Competitive Comparison of Luye Pharma Group's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Luye Pharma Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Luye Pharma Group's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Luye Pharma Group's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Luye Pharma Group's EV-to-EBITDA falls into.



Luye Pharma Group EV-to-EBITDA Calculation

Luye Pharma Group's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=1599.892/267.194
=5.99

Luye Pharma Group's current Enterprise Value is €1,599.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Luye Pharma Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €267.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Luye Pharma Group  (STU:LUP) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Luye Pharma Group's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.324/0.018
=18.00

Luye Pharma Group's share price for today is €0.324.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Luye Pharma Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €0.018.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Luye Pharma Group EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Luye Pharma Group's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Luye Pharma Group Business Description

Traded in Other Exchanges
Address
No. 15 Chuang Ye Road, High-tech Industrial Development Zone, Shandong, Yantai, CHN, 264003
Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on developing, producing, and selling pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for global use in Asia, Europe, and the United States.

Luye Pharma Group Headlines

No Headlines